Orlando, FL -- (SBWIRE) -- 09/16/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Merck & Co., Inc.(NYSE:MRK), Charles Schwab Corp (NYSE:SCHW).
Merck & Co., Inc.(NYSE:MRK) shares fell 0.13% and closed at $47.79. Merck (MRK), known as MSD outside the United States and Canada, and AstraZeneca (AZN) on Sept. 11 announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer.
Additionally, the company on Sept. 9 announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology. If approved, corifollitropin alfa would be the first sustained follicular stimulant for use in a fertility treatment regimen.
Are investors worried about the recent updates with MRK? Find out with a free trend analysis HERE
Charles Schwab Corp (NYSE:SCHW) stock declined 0.18% to $22.03. While students work hard to finish college, many lack the practical coaching and skills to help them land their first job. To help bridge this gap for University of Central Florida (UCF) students. Schwab’s employee resource group, Black Professionals at Charles Schwab (BPACS), has teamed up with UCF’s Multicultural Student Center for its second year of the UCF Bridge Development Program. This six-session, weekend program offers students and recent graduates the opportunity to gain practical and essential business skills to effectively transition from classroom to career. The biweekly program begins Saturday, Sept. 14.
Additionally, On Sep 3, 2013, Zacks reaffirmed their Neutral recommendation on The Charles Schwab Corporation (SCHW). Though the company reported lower-than-expected second-quarter results, the initiatives to improve capital ratios and effective capital deployment activities are impressive.
Is SCHW going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)